|
Mar 12
|
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
|
|
Mar 6
|
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
|
|
Nov 3
|
Genprex to Present at BIO-Europe 2023
|
|
Aug 31
|
Genprex Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation
|
|
Jul 12
|
Genprex Reports Positive Results From Phase 1 Acclaim-1 Clinical Trial
|
|
Jul 8
|
Genprex's Unique Treatment Paradigm Featured in Bell2Bell Podcast
|
|
Jul 6
|
IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc.
|
|
Jul 6
|
Genprex Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination
|
|
Jul 5
|
Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers
|
|
May 2
|
Sidoti's Micro-Cap Virtual May Conference
|